ப்ரொஃபெஸர் க்கு அணு மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunomodulatory drugs improve the success rate of cancer therapies
Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide, have significantly improved the therapy of hematologic malignancies such as multiple myeloma.
Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action in this class of medications. At the same time, they identified new innovative targeted cancer therapies.
The drug thalidomide was sold as a sedative under the trade name Contergan in the 1950s and 1960s. At the time, its side-effects triggered one of the largest pharmaceutical scandals in history: The medication was taken from the market after it became known that the use of Contergan during pregnancy had resulted in over 10,000 cases of severe birth defects. ....

Arne Skerra , Vanesa Fern , Florian Bassermann , Michael Heider , Wolfgang Weber , Emily Henderson , Technical University Of Munich , Professor For Nuclear Medicine , Technical University , Nuclear Medicine , Biological Chemistry , Birth Defects , Multiple Myeloma , வனேசா ஃபெர்ன் , மைக்கேல் ஹைடர் , ஓநாய் வெபர் , எமிலி ஹென்டர்சன் , தொழில்நுட்ப பல்கலைக்கழகம் ஆஃப் முனிச் , ப்ரொஃபெஸர் க்கு அணு மருந்து , தொழில்நுட்ப பல்கலைக்கழகம் , அணு மருந்து , உயிரியல் வேதியியல் , பிறப்பு குறைபாடுகள் , பல மைலோமா ,